{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:43:12Z","timestamp":1782776592212,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint blockade has emerged as a highly effective treatment for patients with metastatic melanoma and cutaneous squamous cell carcinoma. Nivolumab blocks the interactions between programmed cell death protein 1 and programmed death ligand 1 allowing for activation of a latent immune response against the malignancy. Ipilimumab binds to and blocks cytotoxic T-lymphocyte-associated protein 4, alleviating the negative regulation of T-cell activation that is mediated by that checkpoint. Combination therapy with nivolumab and ipilimumab is associated with longer overall survival at 5 years compared with nivolumab monotherapy. Solid organ transplant recipients have a significantly higher risk of malignancies compared with the general population. There is limited data surrounding the efficacy of combination immunotherapy in solid organ transplant recipients, as these patients were excluded from seminal trials due to risk of organ rejection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentations<\/jats:title>\n                  <jats:p>Here we present four cases of combination immunotherapy in kidney transplant recipients. Three patients had metastatic melanoma, and one patient had metastatic cutaneous squamous cell carcinoma. Two patients had radiographic responses from immunotherapy, one patient had stable disease, and one patient had disease progression. Only one patient had biopsy-proven rejection. At last follow-up, three patients had functioning grafts, though one required hemodialysis after treatment, and one patient succumbed to disease, but graft function remained intact throughout her course.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These cases describe the use of ipilimumab and nivolumab combination immunotherapy for cutaneous malignancies in kidney transplant recipients. They highlight the potential to preserve kidney graft function while effectively treating the disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000908","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T05:44:47Z","timestamp":1591335887000},"page":"e000908","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03816332","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-1627","authenticated-orcid":false,"given":"Megan H","family":"Trager","sequence":"first","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-5469","authenticated-orcid":false,"given":"Shana M","family":"Coley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Division of Renal Pathology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dube","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ingham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz H","family":"Samie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J","family":"Geskin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brouder","sequence":"additional","affiliation":[{"name":"Ocean Renal Associates, Brick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Saenger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"2025100306304400000_8.1.e000908.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"2025100306304400000_8.1.e000908.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100306304400000_8.1.e000908.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2025100306304400000_8.1.e000908.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100306304400000_8.1.e000908.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2025100306304400000_8.1.e000908.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025100306304400000_8.1.e000908.7","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","author":"Fisher","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025100306304400000_8.1.e000908.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100306304400000_8.1.e000908.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100306304400000_8.1.e000908.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592"},{"key":"2025100306304400000_8.1.e000908.11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaoncol.2015.5137","article-title":"Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada","volume":"2","author":"Acuna","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100306304400000_8.1.e000908.12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjd.14153","article-title":"Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study","volume":"174","author":"Krynitz","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025100306304400000_8.1.e000908.13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/tri.13011","article-title":"Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study","volume":"30","author":"Fattouh","year":"2017","journal-title":"Transpl Int"},{"key":"2025100306304400000_8.1.e000908.14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-6143.2012.04292.x","article-title":"A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population","volume":"13","author":"Harwood","year":"2013","journal-title":"Am J Transplant"},{"key":"2025100306304400000_8.1.e000908.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.062"},{"key":"2025100306304400000_8.1.e000908.16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canep.2010.07.002","article-title":"Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center","volume":"35","author":"Wisgerhof","year":"2011","journal-title":"Cancer Epidemiol"},{"key":"2025100306304400000_8.1.e000908.17","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.3.301"},{"key":"2025100306304400000_8.1.e000908.18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ctrv.2017.12.004","article-title":"Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients","volume":"63","author":"Chae","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2025100306304400000_8.1.e000908.19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2025100306304400000_8.1.e000908.20","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"2025100306304400000_8.1.e000908.21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1"},{"key":"2025100306304400000_8.1.e000908.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100306304400000_8.1.e000908.23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100306304400000_8.1.e000908.24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1080\/0284186X.2018.1479069","article-title":"Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients","volume":"57","author":"Smedman","year":"2018","journal-title":"Acta Oncol"},{"key":"2025100306304400000_8.1.e000908.25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"2025100306304400000_8.1.e000908.26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"2025100306304400000_8.1.e000908.27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676"}],"updated-by":[{"DOI":"10.1136\/jitc-2020-000908corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:30:54Z","timestamp":1759498254000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,4]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2020-000908"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000908","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}